Multiple Myeloma
Article
10 Important VA Studies You Might Have Missed at ASH
Lost amid the headlining news at the Association American Society of Hematology meeting last week were significant research findings from VA...
News
P-BCMA-101 gains FDA regenerative medicine designation
The autologous CAR T-cell therapy being developed for multiple myeloma received regenerative medicine advanced therapy designation from the FDA....
News
What’s the Impact of Osteoporosis in Multiple Myeloma?
The researchers examined the relationship between the Fracture Risk Assessment Tool and the risk of death in women.
Conference Coverage
Will quad therapy become the new standard in myeloma?
NEW YORK – Phase 2 studies have shown high response rates for four-drug combinations targeting multiple myeloma.
Conference Coverage
STORM trial shows response in penta-refractory myeloma
Selinexor and low-dose dexamethasone produced a “clinically meaningful benefit” in the phase 2 trial.
Conference Coverage
Occurrence of Skeletal-Related Events in Multiple Myeloma and Prostate Cancer Patients Receiving Standard Versus Extended-Interval Zoledronic Acid
News
Fracture risk linked to mortality in women with myeloma
Researchers identified osteoporosis as an important prognostic factor in postmenopausal women.
News
Treatment simulation could help personalize myeloma therapy
A simulation helped identify whether patients would benefit most from treatment with bortezomib or lenalidomide.
News
Myeloma frailty index predicts survival based on biological age
The index, developed after a retrospective analysis of 2.7 million records of noncancer patients and validated with records for 305 multiple...
News
Promising phase 3 results for ixazomib in multiple myeloma
The drug met the primary endpoint in a phase 3 study of maintenance therapy after stem cell transplant.